Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 13.
doi: 10.1007/s12035-025-05142-7. Online ahead of print.

Prediction of Post-Stroke Cognitive Impairment Based on Iron Metabolism Parameters: Results From A Prospective Study

Affiliations

Prediction of Post-Stroke Cognitive Impairment Based on Iron Metabolism Parameters: Results From A Prospective Study

Chunxiao Wei et al. Mol Neurobiol. .

Abstract

Disruption of iron homeostasis is associated with the pathogenesis of neurological disorders. This study aims to elucidate the correlation between serum iron metabolism profiles and the occurrence of post-stroke cognitive impairment (PSCI). Acute ischemic stroke (AIS) patients (n = 500) were enrolled, and serum iron metabolism parameters were collected at baseline. Cognitive abilities, including global cognition, episodic memory, language proficiency, attention, and executive function, were successfully assessed in participants six months after the AIS event (n = 224, mean age = 62). Multivariate logistic regression analysis was employed to screen for iron metabolism indicators influencing PSCI. A general linear model was used to analyze the correlation between total iron-binding capacity (TIBC) and overall cognitive function as well as performance in various cognitive domains. Additionally, we constructed a nomogram model to predict PSCI risk and validated its performance. The results revealed that the TIBC levels were significantly lower in the PSCI group. Elevated TIBC levels may represent a potential protective factor against PSCI development (OR = 0.940, 95% CI = 0.894-0.989, p = 0.018). Furthermore, higher serum TIBC levels were associated with better overall cognitive function, episodic memory, and language proficiency. The nomogram model constructed using age, gender, education level, National Institutes of Health Stroke Scale (NIHSS) score, and TIBC variables demonstrated good predictive performance for PSCI risk (AUC = 0.761, 95%CI = 0.696-0.825). In conclusion, serum TIBC is a potential biomarker for PSCI and is closely associated with cognitive ability.

Keywords: Acute ischemic stroke; Iron metabolism; Post-stroke cognitive impairment; Total iron binding capacity.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no competing interests. Ethics Approval and Consent to Participate: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the First Hospital of Jilin University. Informed consent was obtained from all individual participants included in the study. Clinical Trial Number: Not applicable.

Similar articles

References

    1. Mijajlovic MD, Pavlovic A, Brainin M, Heiss WD, Quinn TJ, Ihle-Hansen HB et al (2017) Post-stroke dementia - a comprehensive review. BMC Med 15(1):11. https://doi.org/10.1186/s12916-017-0779-7 - DOI - PubMed - PMC
    1. Kim KY, Shin KY, Chang KA (2022) Potential biomarkers for post-stroke cognitive impairment: a systematic review and meta-analysis. Int J Mol Sci 23(2). https://doi.org/10.3390/ijms23020602
    1. Huang YY, Chen SD, Leng XY, Kuo K, Wang ZT, Cui M et al (2022) Post-stroke cognitive impairment: epidemiology, risk factors, and management. J Alzheimers Dis 86(3):983–999. https://doi.org/10.3233/JAD-215644 - DOI - PubMed
    1. Todorich B, Pasquini JM, Garcia CI, Paez PM, Connor JR (2009) Oligodendrocytes and myelination: the role of iron. Glia 57(5):467–478. https://doi.org/10.1002/glia.20784 - DOI - PubMed
    1. Gleason A, Bush AI (2021) Iron and ferroptosis as therapeutic targets in alzheimer's disease. Neurotherapeutics 18(1):252–264. https://doi.org/10.1007/s13311-020-00954-y - DOI - PubMed

LinkOut - more resources